Patients with metastatic renal cell cancer historically have had a poorprognosis, and attempts with hormonal therapy and chemotherapy have haddisappointing results. In this exclusive Urology Times interview, W. MarstonLinehan, MD, discusses new treatment strategies for renal cell carcinoma,including multimodality therapy with surgery and systemic therapy, and adoptiveimmunotherapy. Dr. Linehan is chief of urologic surgery at the NationalCancer Institute, Bethesda, MD. UT Editorial Consultant Andrew C. Novick,MD, chairman of the Cleveland Clinic Urological Institute, conducted theinterview.
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.